Psilera Names Magali Haas as Chief Medical Officer
Psilera, Inc. has reached an exciting milestone by appointing Magali Haas, MD/PhD, as the Chief Medical Officer. This strategic addition to the team is set to enhance Psilera's clinical development strategy, particularly for its next-generation neuroplastogens aimed at treating neuropsychiatric disorders.
Expanding Leadership for Growth
The experience that Dr. Haas brings is remarkable, with over 25 years in pharmaceutical research and development. Her competency will significantly bolster Psilera’s ongoing mission to develop innovative therapies that can make a real difference in the lives of patients struggling with neuropsychiatric disorders. Dr. Chris Witowski, Co-Founder and CEO of Psilera, noted how her leadership aligns seamlessly with the company's objectives to reveal effective and safe treatments for underserved populations.
Dr. Haas’s Vision for Psilera
In her new role, Dr. Haas aims to leverage her extensive background in advancing neuroscience research into FDA-approved drugs. With a proven history of leading successful Phase II and III global clinical trials, Dr. Haas will be instrumental in navigating Psilera's promising pipeline through the complexities of regulatory approvals.
Advancing Clinical Development
One of the core projects in focus for Dr. Haas will be the development of PSIL-006, a pioneering therapeutic targeting frontotemporal dementia (FTD). Her leadership experience, including her tenure as Founder and CEO of Cohen Veterans Bioscience, positions her uniquely to guide Psilera’s aspirations within the competitive biopharmaceutical landscape.
Dr. Haas expressed her enthusiasm in joining Psilera, recognizing it as a leader in next-generation neuropsychiatric medicine. Her commitment to advancing innovative treatments will resonate with Psilera's goals to improve patient outcomes for those affected by debilitating brain disorders.
Recent Achievements and Future Directions
2025 has shown promising growth for Psilera, made evident by a successful IP licensing agreement with atai Life Sciences and a noteworthy $2 million research grant from the National Institutes of Health (NIH). Dr. Haas's presence will undoubtedly reinforce Psilera's commitments as it pushes forward with key clinical assets, demonstrating their capacity to address critical mental health needs.
About Psilera
Psilera is charting new territory as a leading biopharmaceutical company focused on developing advanced treatments for neuropsychiatric and neurodegenerative disorders. Their commitment extends across two partnered, late-stage clinical programs, along with an entirely owned pipeline that includes the promising PSIL-006. Psilera strives for excellence in scientific methodologies, continuously seeking to enhance the patient experience globally.
The team at Psilera is dedicated to creating treatment options tailored to serve those often overlooked in today's healthcare ecosystem, affirming its mission and values in the biopharmaceutical arena.
Frequently Asked Questions
What is Psilera known for?
Psilera is dedicated to developing breakthrough therapies for neuropsychiatric disorders, focusing on innovative neuroplastogens.
Who is Dr. Magali Haas?
Dr. Haas is a distinguished neuroscientist with over 25 years of pharmaceutical R&D experience and is now the Chief Medical Officer at Psilera.
What is the significance of PSIL-006?
PSIL-006 is a novel therapeutic targeting frontotemporal dementia, representing a crucial asset in Psilera's pipeline for treating severe brain disorders.
How does Psilera support patient care?
By focusing on underserved populations, Psilera aims to ensure access to safe and effective treatments to improve the quality of life for affected patients.
What recent achievements has Psilera accomplished?
Notable recent milestones for Psilera include a successful licensing agreement with atai Life Sciences and receiving a $2 million grant from the NIH.
